Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1688815 | 0.90 | POLB (0.47) | MAPTALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL7438829 | 0.86 | ALDH1A1 (0.57) | MAPTALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL303932 | 0.85 | PKM (0.46) | MAPTALDH1A1RAB9ANPC1HPGD | |
| Hydrochloric Acid SCHEMBL1169286 | 0.83 | PKM (0.45) | MAPTALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL1039226 | 0.83 | MAPT (0.47) | MAPTALDH1A1AGTR1TDP1MEN1 | |
| SCHEMBL7251960 | 0.83 | ALDH1A1 (0.53) | MAPTALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL9080144 | 0.83 | LIPG (0.46) | MAPTALDH1A1RAB9ANPC1HPGD | |
| SCHEMBL24224237 | 0.82 | PTPRC (0.57) | MAPTRAB9ANPC1SMN1; SMN2EPHX2 | |
| SCHEMBL9135786 | 0.82 | MAPT (0.52) | MAPTALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5807704 | 0.82 | POLB (0.42) | MAPTALDH1A1RAB9ANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306677-A1 | COMPOSITIONS AND METHODS FOR MAKING HYBRID POLYPEPTIDES | YALE UNIVERSITY | 2022-09-29 | — | — | US | disclosed |
| EP-2300481-B1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME (US) | 2015-09-30 | — | — | EP | disclosed |
| US-8530483-B2 | Substituted azabenzoxazoles | MERCK SHARP & DOHME CORP. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| EP-1603883-B1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-28 | — | — | EP | disclosed |
| US-20110212031-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME CORP. | 2011-09-01 | — | — | US | disclosed |
| US-20110085985-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME LLC | 2011-04-14 | — | — | US | disclosed |
| EP-2308848-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | Janssen Pharmaceutica NV (BE) | 2011-04-13 | — | — | EP | disclosed |
| EP-2300481-A2 | NOVEL SUBSTITUTED AZABENZOXAZOLES | Merck Sharp & Dohme Corp. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009155017-A2 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK & CO., INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-12-04 | — | — | US | disclosed |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306677-A1 | COMPOSITIONS AND METHODS FOR MAKING HYBRID POLYPEPTIDES | NSUN3, TARBP1, TRDMT1 | MAPT 3465/4885ALDH1A1 3034/4885RAB9A 3868/4885 |
| US-20110085985-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | APBA1, APP, BACE1 | MAPT 23/4885ALDH1A1 2376/4885RAB9A 4035/4885 |
| US-20040192728-A1 | Quinoline-derived amide modulators of vanilloid VR1 receptor | TRPV1, OPRL1, TRPV2 | MAPT 4519/4885ALDH1A1 1216/4885RAB9A 2453/4885 |
| US-20080300236-A1 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR | TRPV1, OPRL1, TRPV2 | MAPT 4519/4885ALDH1A1 1216/4885RAB9A 2453/4885 |
| US-20110212031-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MAOB, MAOA, AANAT | MAPT 107/4885ALDH1A1 509/4885RAB9A 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.